Exploring Three High Growth Tech Stocks In The United States

The market has been flat in the last week but has risen 21% in the past 12 months, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks can be crucial for investors looking to capitalize on promising opportunities within a steadily advancing market.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
TG Therapeutics	28.62%	43.05%	★★★★★★
Sarepta Therapeutics	24.22%	44.94%	★★★★★★
Ardelyx	27.44%	65.50%	★★★★★★
Super Micro Computer	20.76%	28.05%	★★★★★★
Iris Energy	69.80%	125.09%	★★★★★★
G1 Therapeutics	27.57%	57.75%	★★★★★★
Invivyd	42.85%	71.50%	★★★★★★
Amicus Therapeutics	20.45%	61.85%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 250 stocks from our US High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Ascendis Pharma (NasdaqGS:ASND)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Ascendis Pharma A/S is a biopharmaceutical company dedicated to developing therapies for unmet medical needs, with a market cap of $7.96 billion.

Operations: The company focuses on developing therapies for unmet medical needs, generating €329.02 million in revenue from its biotechnology segment. With a market cap of approximately $7.96 billion, Ascendis Pharma A/S leverages its proprietary TransCon technology to create innovative treatments.

Ascendis Pharma's recent FDA approval for YORVIPATH® highlights its innovative approach to treating hypoparathyroidism, a condition affecting up to 90,000 people in the U.S. With revenue forecasted to grow 36.5% annually, Ascendis is leveraging its R&D investments—$1.2 billion over the past five years—to drive future growth. Despite current unprofitability, earnings are expected to surge by 66.54% per year as new treatments like TransCon PTH gain traction in global markets including Canada and Japan.

• Click here to discover the nuances of Ascendis Pharma with our detailed analytical health report.

• Explore historical data to track Ascendis Pharma's performance over time in our Past section.

AvePoint (NasdaqGS:AVPT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: AvePoint, Inc. offers a cloud-native data management software platform across North America, Europe, Middle East, Africa, and Asia Pacific with a market cap of $2.01 billion.

Operations: The company's primary revenue stream is from its software and programming segment, generating $299.88 million. Its business focuses on providing cloud-native data management solutions across various regions including North America, Europe, Middle East, Africa, and Asia Pacific.

AvePoint's recent earnings report showed a revenue increase to $77.96 million in Q2 2024 from $64.87 million the previous year, alongside a net loss of $12.81 million, slightly higher than last year's $12.59 million loss. The company has forecasted annual revenue growth of 19%, with R&D expenses at 17% of total revenues, highlighting its commitment to innovation and product development. Notably, AvePoint repurchased 652,582 shares for $5.41 million this quarter, reflecting confidence in its growth trajectory despite current unprofitability. The introduction of AvePoint Cloud Backup Express enhances data protection capabilities by leveraging Microsoft 365 Backup Storage for faster recovery times and robust security measures against ransomware attacks—a critical feature as organizations increasingly adopt multi-cloud strategies (89% according to Gartner). This strategic move not only strengthens AvePoint's market position but also aligns with industry trends towards comprehensive cloud-based solutions for enterprise data management and protection.

• Get an in-depth perspective on AvePoint's performance by reading our health report here.

• Examine AvePoint's past performance report to understand how it has performed in the past.

QuinStreet (NasdaqGS:QNST)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: QuinStreet, Inc. is an online performance marketing company that offers customer acquisition services for clients both in the United States and internationally, with a market cap of approximately $1.10 billion.

Operations: QuinStreet generates revenue primarily through its Direct Marketing segment, which accounted for $613.51 million. The company focuses on providing customer acquisition services across various industries in both domestic and international markets.

QuinStreet's recent financial results highlight a significant turnaround, with Q4 2024 revenue jumping to $198.32 million from $130.31 million the previous year, and net loss narrowing to $2.16 million from $55.89 million. The company forecasts robust growth in Auto Insurance, expecting Q1 2025 revenue between $220-$230 million and full fiscal year revenue of up to $850 million—a 34% increase year-over-year at the midpoint. Notably, QuinStreet's R&D expenses have been strategically aligned with its growth ambitions; despite unprofitability, earnings are projected to grow by an impressive 116.07% annually over the next three years, indicating strong future potential in a competitive market landscape where innovation is crucial for sustained success.

• Navigate through the intricacies of QuinStreet with our comprehensive health report here.

• Gain insights into QuinStreet's past trends and performance with our Past report.

Key Takeaways

• Click this link to deep-dive into the 250 companies within our US High Growth Tech and AI Stocks screener.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com